A $150 million settlement has been approved in the class action lawsuit filed on behalf of investors who bought the company's common stock in 2000 and 2001. The suit alleged that the company had improperly booked $1.5 billion in revenue in 2000 and 2001 by coaxing wholesalers to buy more of its drugs than they could sell. (Sep-02-04)
If you have a similar problem and would like to be contacted by a lawyer at no obligation, please fill in our form on the right
to submit your complaint.